A review of recent findings from several FDA Post-Marketing Adverse Drug Experience inspections will be discussed using Warning Letters to identify observations.

Have an account?

Drug Safety and Pharmacovigilance Across the Product Lifecycle

Session 18: FDA Warning Letters

Session Chair(s)

Mark Vieder, MBA, RPh

Be informed and stay engaged.